Motley Fool Asset Management LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 7,012 shares of the biopharmaceutical company’s stock, valued at approximately $5,317,000.
Several other large investors have also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $5,682,636,000. State Street Corp boosted its stake in Regeneron Pharmaceuticals by 3.6% in the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after acquiring an additional 170,210 shares in the last quarter. Bank of America Corp DE grew its holdings in Regeneron Pharmaceuticals by 8.5% in the second quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company’s stock worth $805,023,000 after purchasing an additional 101,469 shares during the last quarter. Amundi grew its holdings in Regeneron Pharmaceuticals by 0.4% in the second quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company’s stock worth $631,983,000 after purchasing an additional 3,742 shares during the last quarter. Finally, Legal & General Group Plc purchased a new position in Regeneron Pharmaceuticals in the second quarter worth $473,872,000. Institutional investors own 83.31% of the company’s stock.
Insider Activity at Regeneron Pharmaceuticals
In related news, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director directly owned 603 shares of the company’s stock, valued at $512,550. This represents a 39.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of the firm’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares of the company’s stock, valued at $36,960,559.10. This trade represents a 7.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on the company. Robert W. Baird upped their price target on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the stock a “neutral” rating in a research report on Friday, July 31st. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Truist Financial boosted their target price on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. Wells Fargo & Company upped their target price on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Finally, Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a research report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $847.90.
Read Our Latest Stock Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Stock Down 0.3%
REGN stock opened at $813.27 on Thursday. The stock has a market capitalization of $83.73 billion, a PE ratio of 20.10, a price-to-earnings-growth ratio of 1.36 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a 52 week low of $591.52 and a 52 week high of $859.34. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average of $791.72 and a 200 day moving average of $737.14.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. Regeneron Pharmaceuticals’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $12.81 EPS. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current year.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.
Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.
Featured Articles
- Five stocks we like better than Regeneron Pharmaceuticals
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
